Introduction
Traumatic brain injury (TBI) is a leading cause of acquired epilepsy [1] . In veterans, 57% of seizures can be linked to TBI [2] . Immediately following injury, the brain undergoes distinct electrophysiological changes, which can be detected with electroencephalography [3] . Seizures not only account for heightened morbidity and mortality in the early stages following TBI, but also remain the leading cause of death several years following TBI [4] . Seizure prophylaxis is commonly employed post-injury with variable success [5] . The prophylaxis is primarily used for prevention of single occurrence acute post-traumatic seizure (PTS) but has little efficacy on preventing the recurrent chronic seizures that define post-traumatic epilepsy (PTE). The underlying mechanisms that may contribute to PTE are poorly understood making PTE more likely to be refractory to medical management [6] . Despite prophylaxis treatment, 4-53% of TBI patients still have chronic seizures [7] . Unfortunately, few novel treatments for the prevention of PTE have been discovered over the past century [8] .
In order to improve treatment options, it is important to elucidate the underlying pathophysiology of PTE. To do so, preclinical models should be utilized to understand intrinsic biochemical mechanisms of injury. Animal models can be used to study natural progression toward seizure activity following neural injury [8] . In the past, experimental approaches for studying PTE frequently employed seizure-inducing agents such as kainic acid or pentylenetetrazol (PTZ). While such models have provided compelling evidence that changes in glutamate signaling and GABA-A channels may play a role in acute seizure onset following TBI, they have failed to answer how the natural progression of TBI contributes to late onset seizures [9] . How genetic regulation affects these acute receptor and channel changes is poorly understood and is a topic worthy of investigation [10] . It has been shown that glutamate signaling increases in response to decreased GABAnergic activity [11] , and as we discuss later, the phenomenon is likely due to microRNA regulation. The key unanswered question is why some individuals recover from these transient signal changes while others go on to develop PTE [12] . Recent evidence from pre-clinical rodent models suggests that neuroinflammation may play a key physiologic role in shifting the balance toward PTE [13] . We discuss in particular the role of toll-like receptors and how at extended post-injury time points, neuroinflammation may contribute to loss of hippocampal interneurons [9] . Important knowledge has been obtained from both clinical and pre-clinical studies. TBI patients with cerebral contusion and subsequent inflammation are at higher risk for epilepsy than those without contusion [14] . Mechanisms triggered by neuroinflammation such as oxidative stress and mitochondrial dysfunction appear to add to the onset and progression of epilepsy post-TBI and may contribute to the neurodegeneration that has been reported with PTE [15] .
In this paper, we will begin with a review of epidemiology and go through treatment options, preclinical models, the biochemical cascade of PTE development, and novel pharmaceutical targets. The epidemiology and symptoms associated with PTE will be discussed with particular emphasis on the patient's gender, injury severity, primary mechanism of injury, and genetic background. We will also highlight current treatment options used for prophylaxis therapy of acute PTS elaborating upon mechanism of action and potential side effects. Potential reasons for treatment ineffectiveness for PTE will be postulated. In order to improve outcomes and reduce late onset seizure occurrence following TBI, biochemical pathways should be investigated using well-designed pre-clinical models. The pros and cons of available models will be outlined with a subsequent overview of what is currently known about the biochemical mechanisms for seizure development post-TBI. Finally, we will address important biochemical pathways warranting further investigation and discuss how these pathways can contribute to the discovery of novel pharmaceutical targets. Because no current treatment option has been shown to completely prevent PTE, the long-term goal is to foster improved treatment approaches by targeting specific and important mechanisms of injury progression. By developing targeted therapy, it is plausible that within the century we can see a drastic reduction in late onset seizure post-TBI.
Epidemiology and symptoms
Seizures are a major complication that can occur after TBI, and the development of epilepsy is a serious concern for neurotrauma patients. After TBI, the occurrence of seizures has been categorized as immediate (<24 h), early (1-7 d), or late (>1 wk) [16] . According to the National Institute of Neurological Disorders and Stroke, epilepsy requires the occurrence of two or more spontaneous seizures. The International League Against Epilepsy expanded the definition to include 1 spontaneous seizure with a risk for future seizure [17] . TBI associated with at least two unprovoked, late onset seizures constitutes the diagnosis of PTE; otherwise, the diagnosis is PTS [18] . Additional definitions related to PTE revolve around the degree of head trauma. Many investigators currently use the following: (1) mild TBI (loss of consciousness less than 30 min and no skull fracture); (2) moderate TBI (loss of consciousness more than 30 min and less than 24 h, with or without skull fracture); and (3) severe TBI (loss of consciousness greater than 24 h, with contusion, hematoma, or skull fracture) [19, 20] .
Epidemiology
Epidemiological studies have found that PTE accounts for 10-20% of symptomatic epilepsy in the general population, and 5% of all epilepsies [21] . Regarding PTE caused by war, the incidence is much higher in veterans than the incidence in civilian populations. The total incidence of PTE in the civilian population is approximately 2% [21] , but in the veteran population it reaches as high as 25% when patients are followed 5 or more years from time of combat [22] . Moreover, the incidence of epilepsy ranges from 22 to 43% (median 34%) five years after TBI in civilians, and the incidence is almost 50% 10 or more years after injury for veterans.
Clinical presentation
The latency from TBI to the occurrence of the first seizure varies greatly [4] . In general, approximately 80% of individuals who develop PTE, have their first seizure within the first 12 months post-injury, and more than 90% by the end of the second year [23] . After the first late onset seizure (>1 wk from injury), 86% of patients have reported a second seizure within 2 years [24] .
Several clinical studies have identified the types of late seizures observed after TBI, which are varied. In a study of 60 patients with moderate to severe TBI, 52% developed generalized seizures, 33% had focal seizures, and 15% had focal seizures with secondary generalization [24] . In another study of 123 patients with PTE, representing 4% of all patients evaluated in the epilepsy monitoring unit, most of them had localization-related epilepsy: 57% had temporal lobe epilepsy, 35% had frontal lobe epilepsy, and 3% each had parietal and occipital lobe epilepsy [6] . Of patients with temporal lobe epilepsy, 44% had mesial temporal sclerosis, 26% had temporal neocortical lesions, and 30% were non-lesional [6] .
PTE may present with a myriad of other sequelae. In particular, PTE has been associated with insomnia in veterans where they have an inability to fall or stay asleep [25] . In a large populationbased study (N = 1961), persons identified as having depression at discharge have been found to be almost twice as likely to develop PTE [26] . In the same study, participants with three or more chronic comorbid conditions, such as cardiovascular disease or diabetes, at discharge had increased risk of PTE [26] . It has yet to be determined whether the co-morbidities precede development of PTE or are the result of traumatic brain damage.
Risk factors
A critical determinant for PTE is TBI severity [26] . In a population-based clinical study (N = 4541) of TBI cases occurring between 1935 and 1984 in Olmstead County, Minnesota the investigators found that the five-year cumulative probability of unprovoked seizures was 0.7% in patients with mild TBI, 1.2% for moderate TBI, and 10.0% for severe TBI [19] . For the cohort with 30 years of follow-up, the cumulative incidence was 2.1% for mild TBI, 4.2% for moderate TBI, and 16.7% for severe TBI [19] . In a separate study, Englander and colleagues prospectively followed 647 patients admitted to any of four trauma centers within 24 h of injury. The authors identified a ''dose-response'' for the number of cerebral contusions and the development of late seizures-the cumulative probability of unprovoked seizures by 2 years was approximately 25% for patients with multiple contusions, compared to 8% for a single contusion and 6% for no contusions. For those with very mild TBI (no acute loss of consciousness, amnesia, confusion, or neurological deficit), only 3 (0.1%) out of 2999 patients developed seizures within 1 year of follow-up compared to 1 (0.1%) out of 994 of the control group with orthopedic injuries, suggesting that the incidence of seizures was not significantly greater than the general population [27] .
Other key risk factors for more severe injury include dural penetration, depressed skull fracture, intracranial hematoma, and loss of consciousness or amnesia for more than one day [28] . Hemorrhage and skull fracture are often seen with more severe TBI [29] . Hemorrhage and skull fracture increase inflammation and neuronal excitability, which effectively decreases the threshold for seizures [30] . Neuroinflammation remains elevated well past 8 days in severe TBI, which may account in part for the development of late onset seizures [31] .
In addition, the presence of early seizures may predispose individuals to the development of late PTE [22] . Young children are more prone to early seizures, and adolescents and adults to late seizures [22] . Older age may also increase the risk for PTE [28] . Gender overall does not appear to influence risk for PTE, although females may have a higher risk for PTE after milder injuries compared to males [32] . Warfighters are especially susceptible to the development of PTE [2] .
Recent evidence from genetic association studies supports the view that certain genetic variants may also increase the risk for PTE (Table 1 ). Positive findings in these studies are currently preliminary. They have yet to be confirmed in separate studies or in different populations of patients with PTE. For instance, in patients Note: PTS, post-traumatic seizures; PTE, post-traumatic epilepsy; GCS, Glasgow coma scale; APOE e4, apolipoprotein E epsilon 4; GAD, glutamic acid decarboxylase; CT, computed tomographic.
with moderate or severe TBI (N = 106), the apolipoprotein E epsilon 4 (APOE e4) allele was associated with a 2.4-fold increased risk of late PTS [33] . However, no significant associations were found in Vietnam War veterans with brain injury (N = 199) [34] . Mixed results have been obtained for APOE e4 and GAD as outlined in Table 1 . Additional genetic studies may provide further insights into the pathophysiology of PTE and guide the development of better treatments for PTE. The studies must be sufficiently powered and ideally prospective in nature.
Current treatment options
PTE has been shown to cause secondary damage to the brain. The seizure activity can cause hypoxia, increased intracranial pressure, cerebral edema, intracerebral hemorrhage, increased metabolic demand within the brain, and glutamate excitotoxicity [35] . In order to prevent permanent neurological sequela, current treatment of neurotrauma with regards to seizure development falls into one of two categories: prophylaxis for acute seizure or management of PTE, both of which have focused on the use of antiepileptic drugs (AEDs). To decrease the incidence of seizures posttrauma, the majority of clinicians are prescribing prophylactic medications for patients following head injury [35] . Prophylaxis is currently recommended for severe TBI by leading advisory boards (Brain Trauma Foundation and the American Academy of Neurology) for the first 7 days [4] . While there is evidence that these prophylactic anticonvulsants reduce early seizures, there is no proven benefit for long-term prognosis [36] . Indeed, a metaanalysis of 10 randomized controlled trials showed a pooled relative risk reduction of 0.34 for early seizure prevention indicating that 10 in every 100 patients will be seizure-free from treatment [37] . On the other hand, no beneficial effects on mortality or neurological disability were found regarding the prevention of late-onset seizure. It is also important to note that no randomized controlled trial has shown that one drug is more efficacious than another [38] as outlined for phenytoin, carbamazepine, valproate, and phenobarbital (Table 2) . Randomized trials are difficult to perform because all new treatments must be compared to an already available treatment thereby masking potential benefit. Despite their similar uses, the available medications target different pathways. Thus, before prescribing these medications, consideration of injury severity, patient status, and side effect profile must be carefully reviewed [39] .
Phenytoin
Phenytoin increases the refractory period and reversibly inhibits action potentials [40] . In severe TBI, phenytoin has been found to reduce the incidence of early seizures from 14.2% to 3.6% [41] . Also, this drug should only be used within the first 48 h post-trauma because a randomized control trial showed a trend toward higher mortality when used at later time points [35] . In a separate study, the use of this anticonvulsant beyond 1 week was associated with idiosyncratic side effects (Table 2) [37, 40] . The onset of rashes is also suggested with a RR of 1.57 from a recent meta-analysis [37] . In addition, long-term prophylaxis has not been shown to improve morbidity, mortality, or PTE development with this drug [35] . The current recommendation is early prophylaxis and acute treatment with each episode of seizure activity.
Carbamazepine
Another rarely prescribed medication for prophylaxis is carbamazepine [40] . One preliminary study has demonstrated that carbamazepine reduces PTS by 61% [38] . According to a meta-analysis, early preventive treatment with carbamazepine showed a RR of 0.96 for reduction in mortality and disability [37] . This is consistent with other studies demonstrating no association between early prophylaxis and long-term prognosis. It is important to note that this medication is associated with several side effects and is administered intravenously limiting its use (Table 2 ) [40] . These adverse reactions must be carefully considered before administration and monitored thereafter.
Valproate
Valproate inhibits GABA transaminase increasing GABA levels in the synaptic cleft [40] . Studies have demonstrated a similar efficacy as compared to phenytoin [38] . However, valproate is also associated with a higher mortality [42] . Potential adverse effects of valproate are outlined in Table 2 [40] . Despite its efficacy, this medication cannot be recommended due to increased mortality in patients with PTS [42] .
Phenobarbital
Phenobarbital is also used for prophylaxis [40] . In decreases excitatory neurotransmitter release at the synaptic terminal [43] . This medication has been studied in a randomized controlled trial to determine its effect on patients with severe head trauma. Phenobarbital was prescribed at a serum drug concentration of 10-25 mg/mL 1-month post-trauma for 3 years, and patients were followed for a 5-year duration [38] . Long-term prophylaxis did not show a statistically significant reduction in seizure occurrence. Phenobarbital is also associated with side effects (Table 2 ) [40] . In addition, phenobarbital is more likely to be discontinued compared to other drugs (including carbamazepine, phenytoin, and valproate) due to its adverse reactions [44] . Due to overall limited evidence of efficacy in short-and long-term prevention of seizures as well as numerous adverse effects [44] , this anticonvulsant should be used only after consideration of other therapeutic options.
Overall, with the current regimen, prophylaxis immediately post-injury is effective for reducing early seizures [37] . However, the use of these medications has not been shown to improve longterm prognosis. Moreover, they have narrow therapeutic safety windows, even in patients without brain injury, which may outweigh the limited beneficial effects. 
Pre-clinical models
In order to improve treatment options, pre-clinical models must be designed to understand PTE pathophysiology. Recently, the neurotrauma field has made a push for the development of more predictive pre-clinical models of TBI that are consistent, reproducible, and most importantly, clinically relevant (Table 3) . Pre-clinical TBI models should produce similar mechanisms of injury and pathologies as seen in human TBI, including generation of PTE. Over the past decade, the most common pre-clinical model of PTE is the rat fluid percussion model combined with a PTZ challenge [45] . Other models include a weight-drop combined with PTZ [46] , controlled cortical impact (CCI) combined with PTZ [47] , and CCI combined with electroconvulsive shock as outlined in Table 3 [48] . These models have been used to shed light on novel mechanisms of injury progression leading to seizure. CCI and fluid percussion are typically invasive, in contrast to closedhead injury which is more commonly observed in patients [49] . Blast modeling and weight drop may be more clinically relevant due to simulation of acceleration/deceleration injury and contusion respectively.
Few currently used models can induce the natural progression of PTE without a pharmacologic agent, and require a very severe injury, or require the animals to be very young, or very old and therefore more susceptible to PTE [22] . While a model that induces a natural PTE is ideal, the caveat of increased mortality lies within models of severe TBI. Several reasons account for the limited ability to produce natural progression PTE in rodents. The most prominent reason is lack of detection capabilities. Unlike humans, rodents do not often produce overt signs of seizure-like activity. Therefore brain imaging or electrical scanning becomes imperative to detect activity that may not be represented behaviorally. Additionally, rodents have a shorter lifespan and therefore may not adequately map the time course necessary for PTE development. In order to produce robust effects, an injury model that produces severe brain damage is often utilized.
Thus, while models already exist that exhibit relevant mechanisms of injury and pathologies including PTE, their feasibility for routine experimental studies is limited due to their associated high mortality. As such, an optimized PTE model for the future may be one with a closed-head moderate TBI that could produce a natural seizure over a shorter duration, but continuous seizure activity chronically. At the present time, this type of model has not been established. However, since evidence suggests that blood brain barrier (BBB) disruption contributes to early seizure onset [50] , incorporation of robust BBB disruption is suggested for future model development.
Additionally, future assessments of TBI pre-clinical models should include systematic monitoring of several elements to facilitate model development and optimization. These include determining the length of time to seizure onset and continuance of seizures long-term in such models. Also, assessment of pre-clinical models could benefit from more uniformity in seizure detection, with electroencephalogram (EEG) used to determine the number and type of seizures. Moreover, the use of juvenile rodents may not be the most clinically relevant when extrapolating to the human population who typically sustain a TBI. The use of adult rodents would be beneficial in future studies. Additional research into modeling a more clinically relevant TBI must be undertaken to establish a more natural progression to seizure onset. Recent PTE modeling has decreased the latency of epileptogenesis, but not without a secondary insult using seizure inducing compounds, or electroconvulsive shock [48] . Most PTE models use PTZ as the pharmacological inducer of seizure, with other PTE models using kainic acid following TBI [30] . The choice of which seizure-inducing compound is most relevant depends upon the mechanism under investigation as outlined in Table 3 . PTZ induces seizures by inhibiting the inhibitory neurotransmitter GABA (disinhibition), and KA induces seizures by activating the excitatory neurotransmitter glutamate. KA, for instance, would be a good secondary insult to use after TBI when investigating NMDA triggered mechanisms of excitotoxicity. Although these two compounds are validated within the epilepsy field, the idea of pharmacological secondary insult after TBI warrants further investigation. It is currently unknown what triggers late onset seizures in humans and it may be linked to chronic neuroinflammation or another idiopathic insult. The second hit model can be used to establish a mechanistic pathway for seizure progression; but in order to effectively model PTE pre-clinically increased emphasis must be placed on subthreshold doses that lower seizure threshold. Ideally the model will induce full-blown seizure with a subthreshold pharmacologic intervention or a second-hit of lower intensity.
Mechanisms of injury

Glutamate excitotoxicity
The development of adequate models can help increase understanding about generation of an epileptic foci acutely [51] . Animal models have shown that within the first few days post-injury, disruption of microRNAs facilitates the transition toward epileptic activity [52] . The disrupted microRNAs exacerbate glutamate-mediated excitotoxicity post-injury [53] . The induction of the glutamate toxicity may be orchestrated through iron release from damaged blood cells diffusing across a disrupted BBB [50] . The remaining surviving neurons participate in functional or structural adaptations, such as axonal sprouting, to increase the risk for subsequent hyperexcitability [54] . Concurrent with glutamate changes, a substantial reduction in GABA releasing interneurons within the hippocampus leads to enhanced disinhibition at early time points post-injury [9] .
Neuroinflammation
Several days after injury, the damaged brain region can initiate the cell danger response, which consists of a series of injury cascades that halts normal homeostasis [55] . Part of this response is dependent on mechanistic target of rapamycin (mTOR) signaling, which has been suggested to contribute to tissue damage and continued excitotoxicity [56] . mTOR1c, in particular, has been implicated in the pathology of PTE [57] . Acute neuroinflammation activates Akt, which phosphorylates mTOR and contributes to cell-death [56] . Further research is needed to elucidate the long-term effects of mTOR activation.
Another important subacute response is mediated by tollligands and toll-like receptors. Toll-like receptors trigger the innate immune system and regulate non-NMDA glutamate channels [58] . Following injury, activation of these toll-like receptors can contribute to continued glutamate excitotoxicity out to several weeks [59] . Wang and colleagues showed that toll-like receptors are upregulated following kainic acid administration [60] . Specifically, toll-like receptor 4 is associated with temporal lobe seizures following trauma [61] . Toll-like receptors on glia trigger a robust gliosis response post-injury [62] .
The initial injury cascade is followed by a period of neuroinflammation mediated through activated astrocytes and microglia [63] . Neuroinflammation can last months after injury. Upregulation of phospholipase A2 and lipid metabolism continues to activate this neuroinflammatory cascade several months postinjury [64] . Mutations in the Plaur gene, which traditionally promotes plasmin formation, may make certain individuals more susceptible to sustained neuroinflammation following injury [65] . Reducing this inflammation through selective brain cooling proves promising in preventing late onset seizures in a rodent model [66] . Recent evidence implicates interleukin 1b as a cerebral-spinal fluid marker predictive of persistent neuroinflammation seen with PTE [67] .
Tau pathology
Late onset epilepsy several years post-injury has been associated with tau hyperphosphorylation and neurodegeneration post-injury (Fig. 1) [68] . An imbalance in zinc homeostasis may contribute to tauopathy in PTE patients. An increase in zinc levels has been shown to generate reactive oxygen species in neurons with tau tangles, which may contribute to seizure onset [69] . TBI also causes disruption in A-type potassium channels further leading to release of reactive oxygen species and neuronal damage in the hippocampus [70] . Substantial atrophy of the surrounding entorhinal and perirhinal cortices is commonly seen following initial seizure onset [71] . Furthermore, mTOR complex 1 has been implicated in neurodegeneration leading to sustained seizure activity with increased mossy fiber spreading in the hippocampus [72] . This pre-clinical data is similar to persistent gliosis, cavitation, and hippocampal sclerosis in human TBI patients measured with diffusion tensor tractography [73] . Hippocampal sclerosis is associated with tauopathy in patients with PTE [68] .
Mechanism summary
At acute time points, glutamate excitotoxicity contributes to early onset seizure. Over time secondary injury cascades activate downstream long-term cascades such as mTOR activation and tolllike receptor upregulation. These subacute changes facilitate the transition toward PTE. In conjunction with PTE, tauopathy can develop. Tauopathy can further contribute to seizure generation enhancing chronic neurodegeneration.
Novel targets
Selecting therapeutic compounds that have potential efficacy is dependent on two important features. Does the compound target an important pathway linked to seizure progression, and will it produce limited side effects? Once these questions have been successfully answered, it will be important to classify the compound into rescue therapy or preventative treatment. Rescue therapy reduces the number of seizures once they have started. Preventative treatments stop seizures from occurring or starting at extended time points.
While the historical emphasis has been on medical management and/or prophylaxis of seizures acutely in the post-trauma setting, recent studies have shifted focus to the latent period between the traumatic episode and development of late seizures, occurring years post-injury [4] . These studies have explored numerous therapeutic targets ranging from those modulating neurotransmitters both directly and indirectly (i.e. AEDs), intraceullular signal transduction, cannabinoid receptors, inflammation, induction of hypothermia, and utility of a ketogenic diet [4] . The results of these studies have been reviewed extensively elsewhere [4] but in the following paragraphs we will briefly summarize the findings of these studies.
Rescue therapies
SR141716A, also known as Rimonabant 1 and Acomplia, an inverse agonist of the cannabinoid CB1 receptor previously marketed as an appetite modulator, was tested by Echegoyen and colleagues in pre-clinical studies of seizure threshold post-TBI [75] . Using a lateral fluid-percussion model and kainate to induce seizures at 6 weeks post-TBI, the authors evaluated the ability of SR141716A to modulate the latency to kainate-induced seizures and the total time spent seizing post-TBI [75] . SR141716A administration decreased latency to seizure and decreased total time spent seizing following TBI in comparison to vehicle treatment [75, 76] . No protective effects were observed, however, when the compound was administered 20 min post-injury [76] . Despite promising but limited preclinical studies, the compound was pulled from the market due to elevated rates of depression and suicidal thoughts.
Minozac, a promising anti-inflammatory agent being developed for numerous neurological diseases such as Alzheimer's disease and multiple sclerosis, has been evaluated post-TBI in pre-clinical studies and shown to decrease electroconvulsive shock-induced seizure susceptibility at 1 week post-injury [48] . Whether these effects will persist at later time points and if this compound will be evaluated clinically remains to be seen [76] . Regardless, these preliminary studies show some promise regarding inflammation as a therapeutic target for seizure development post-TBI.
Preventative treatments
Due to the frequently suboptimal results associated with AED use in the management of epilepsy, alternative therapeutic approaches and techniques have been explored at great lengths. One of those most commonly discussed in the clinical literature is the implementation of a ketogenic diet [77] . Ketone bodies have been shown to have anticonvulsant effects with fasting decreasing the amount of seizures in patients with epilepsy ( Fig. 2) [77] . This approach was employed by Schwartzkroin and colleagues in a preclinical study addressing fluorothyl-induced seizure susceptibility following lateral fluid-percussion injury [78] . However, dietary regimen had no effect on seizure susceptibility in this study when considering seizure threshold and duration [76] .
Another non-pharmacological approach to preventing seizures post-TBI previously suggested and evaluated in pre-clinical models is hypothermia. Hypothermia has long been recognized and evaluated as a potential neuroprotective strategy and in some cases has been associated with protective behavioral and biochemical effects, both in pre-clinical and clinical studies of neural injury. Atkins and colleagues evaluated the ability of hypothermia to alter PTZ-induced seizures at chronic time points Fig. 1 . The initial acute injury (hours-days) following TBI induces glutamate excitability and sclerosis. Reactive oxygen species are generated from the resulting hyperexcitability, which damage the cell. This process is regulated by microRNAs. At subacute time points (days-weeks) inflammation occurs from activated toll-like receptors and non-NMDA glutamate receptors. These further insults exacerbate the damage caused by glutamate toxicity and allow free iron to enter the cell. Over time (months-years) this injury contributes to tau aggregation. Tau interacts with zinc to generate further free radical damage reducing the threshold for late onset seizure.
following TBI [66] . The study showed that hypothermia, when administered starting 30 min post-injury for a total of 4 h, reduced the number of seizures induced by PTZ as well as mossy fiber sprouting but had no effect on seizure severity [76] .
Treatment options for drug-resistant PTE
All clinical studies to date have emphasized acute control of seizures post-injury and have failed to identify any agents that successfully modulate seizures chronically (at extended time points post-injury). This is an important consideration because the relative risk of PTE remains heightened even at a decade postinjury, in adults and children [4] .
In spite of widespread AED development (over 15 thirdgeneration AEDs since the 1980s), 30-40% of patients experience unsatisfactory control of seizures [38] . Unsatisfactory control or medical intractability, is defined as the failure of two pharmacological agents to control seizures, and is predicted by the presence of neurologic structural anomalies in the temporal cortex, often found in PTE [74] . Further research is being conducted to investigate the protective properties of supplements such as nacetyl cysteine and progesterone to treat PTE, but the results are so far inconclusive [79, 80] . In patients failing medical management, surgical resection may be an option if a seizure focus can be identified on imaging and/or electrophysiological studies [4] . In patients that are not deemed surgical candidates for resection, other management options are available such as placement of a vagal nerve stimulator [4] .
Future investigation
Future work needs to address the mechanisms involved in the development of recurrent excitatory networks that have been documented in pre-clinical and clinical studies alike related to development of PTE, and the approaches to modulate them. Focusing on approaches to alter excessive and recurrent dendrite outgrowth post-trauma may prove advantageous. For this reason, investigation of molecules and pathways implicated in neuronal outgrowth and development may be warranted. Of particular interest is JNK-mediated signaling, which has been implicated previously not only in pre-clinical and clinical studies related to epilepsy development but also in neurodegeneration associated with TBI [81] . Evaluating potential side effects of targeting JNK pathways must be carefully considered.
As [82] . Importantly, while the aforementioned targets represent direct therapeutic approaches at subacute time points, indirect or upstream signaling pathways may be just as viable. For example, brain-derived neurotrophic factor (BDNF) has long been recognized as playing a role in synaptogenesis and synaptic modification but has also been implicated in epileptogenesis [83] . BDNF exerts an array of effects ranging from gating ion channels to protein phosphorylation to TrkB-mediated activation of intracellular second messenger cascades. All of these changes may successfully modulate functional properties of ion channels [82] .
Conclusion
PTE continues to remain a serious concern following TBI. Despite widespread use of AEDs in the first 7 days following neurotrauma, the prevalence of late-onset seizure has not decreased in the past century and perhaps most importantly, no treatment options are available or recommended for prevention of these delayed seizures. TBI reduces seizure threshold but overall understanding about progression is not well characterized. In order to improve treatment options that can prevent late-onset seizure, clinically relevant pre-clinical models must be developed to examine important mechanistic pathways related to seizure onset. One of the most important pathways warranting further investigation is glutamate excitotoxicity and subsequent damage following TBI. Disinhibition of GABA as shown by the PTZ second hit studies is equally important and should be considered. Another area requiring focused investigation is the relationship between seizure activity and neurodegeneration. Despite the complexity of PTE, novel therapeutics currently being investigated in pre-clinical settings appears promising. As novel approaches and therapeutics are carried forward in a transition toward clinical trials, efficacy, safety, and bioavailability must be carefully considered. Increasing the overall understanding of PTE will aid in the development of selective therapeutics for the treatment and prevention of lateonset seizure in the coming decades.
Key point box 1. Post-traumatic epilepsy is a major concern for traumatic brain injury patients with no effective treatments for preventing late onset seizure. 2. Improving pre-clinical models that adequately represent posttraumatic epilepsy is critical for enhancing our understanding of injury progression. 3. Novel therapies will likely target pathways that are implicated in linking acute injury to chronic changes within the brain.
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